April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Azithromycin Alters ProMMP-2 and TIMP-1 Following Corneal Wounding in an Experimental Animal Model of Diabetic Ocular Complications
J. L. Jacot; T. A. Jacot; S. Hahto; J. Helis; C. J. Sheppard; J. D. Sheppard, Jr.; F. A. Lattanzio, Jr.; P. B. Williams
Author Affiliations & Notes
  • J. L. Jacot
    Pathology and Anatomy,
    Eastern Virginia Medical School, Norfolk, Virginia
  • T. A. Jacot
    Physiological Sciences,
    Eastern Virginia Medical School, Norfolk, Virginia
  • S. Hahto
    Pathology and Anatomy,
    Eastern Virginia Medical School, Norfolk, Virginia
  • J. Helis
    Pathology and Anatomy,
    Eastern Virginia Medical School, Norfolk, Virginia
  • C. J. Sheppard
    Pathology and Anatomy,
    Eastern Virginia Medical School, Norfolk, Virginia
  • J. D. Sheppard, Jr.
    Ophthalmology,
    Eastern Virginia Medical School, Norfolk, Virginia
  • F. A. Lattanzio, Jr.
    T.R. Lee Center for Ocular Pharmacology,
    Eastern Virginia Medical School, Norfolk, Virginia
  • P. B. Williams
    T.R. Lee Center for Ocular Pharmacology,
    Eastern Virginia Medical School, Norfolk, Virginia
  • Footnotes
    Commercial Relationships  J.L. Jacot, Inspire Pharmaceuticals, F; T.A. Jacot, None; S. Hahto, None; J. Helis, None; C.J. Sheppard, None; J.D. Sheppard, Jr., Inspire Pharmaceuticals, F; Insite Pharmaceuticals, F; F.A. Lattanzio, Jr., Inspire Pharmaceuticals, F; P.B. Williams, Inspire Pharmaceuticals, F.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2663. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Azithromycin Alters ProMMP-2 and TIMP-1 Following Corneal Wounding in an Experimental Animal Model of Diabetic Ocular Complications
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      J. L. Jacot, T. A. Jacot, S. Hahto, J. Helis, C. J. Sheppard, J. D. Sheppard, Jr., F. A. Lattanzio, Jr., P. B. Williams; Azithromycin Alters ProMMP-2 and TIMP-1 Following Corneal Wounding in an Experimental Animal Model of Diabetic Ocular Complications. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2663.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To determine the effect of topical azithromycin (AzaSite®) and its vehicle (DuraSite®) on MMP-2 and TIMP-1 in tears of control and galactosemic rats. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), which modulate activity of certain MMPs, are involved in multiple processes in damaged and diseased eyes. MMP-2 is elevated after corneal wounding, ulceration, erosion, collagen remodeling and repair.

Methods: : Male SD rats were randomized into 4 groups (n=6/group) and fed ad lib chow with either 50% starch (control) or 50% D-galactose. The dietary groups were treated bilaterally either with 3x/day 1% AzaSite®or DuraSite® for two months. Tears were collected 2 weeks after induction of a sterile 3 mm central corneal epithelial wound under anesthesia. Tears were placed in Tris (pH 7.4) w/ protease inhibitors. MMP-2 in tears was evaluated by gelatin sepharose affinity precipitation followed by gelatin zymography. Samples were normalized by equal protein load and semi-quantified using NIH-imageJ for integrated density units/per area. Microbead antibody immunoassay was used to determine tear levels of TIMP-1 (ng/ml).

Results: : Tears from galactosemic rats exhibited elevated proMMP-2 relative to control group. Compared to DuraSite® treated galactosemic rats, the AzaSite® treatment suppressed proMMP-2 levels by 38%. Control group showed a 17% decrease in proMMP-2 with AzaSite® compared to DuraSite®. There was a trend towards elevation of TIMP-1 levels in the AzaSite® treated galactosemic rats compared to DuraSite®. No appreciable trend was observed in the control group.

Conclusions: : This study on modulation of tear levels of MMP-2 and TIMP-1 by the antibiotic, AzaSite®, provides preliminary mechanistic data for the use of AzaSite® therapy in the management of ocular surface tissue remodeling/injury, diabetic and neurotrophic keratopathies where corneal MMP levels can be elevated.

Keywords: antibiotics/antifungals/antiparasitics • cornea: tears/tear film/dry eye • wound healing 
© 2009, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept